No Data
No Data
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $7
Evercore ISI Keeps Their Buy Rating on Editas Medicine (EDIT)
Editas Medicine Updates RUBY Trial With Promising Results
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'